Persistent Epithelial Defect Market
The Persistent Epithelial Defect market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted PED symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Persistent Epithelial Defect symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Persistent Epithelial Defect Market Outlook
The Persistent Epithelial Defect market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Persistent Epithelial Defect market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Persistent Epithelial Defect market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Persistent Epithelial Defect market in 7MM is expected to change in the study period 2018–2030.
Key Findings
This section includes a glimpse of the Persistent Epithelial Defect market in 7MM. The market size of PED in the seven major markets was found to be USD 165.3 million in 2020, and the market is estimated to increase for the study period (2018–2030).
The United States Market Outlook
This section provides a total of Persistent Epithelial Defect market size and market size by therapies in the United States.
The United States accounts for the highest PED market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Persistent Epithelial Defect market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Persistent Epithelial Defect market size and market size by therapies in Japan are also mentioned.
Request for sample pages @ Persistent Epithelial Defect Market Size
Table of contents
1. Key Insights
2. Report Introduction
3. Persistent Corneal Epithelial Defects Market Overview at a Glance
3.1. Market Share (%) Distribution of Persistent Corneal Epithelial Defects in 2018
3.2. Market Share (%) Distribution of Persistent Corneal Epithelial Defects in 2030
4. Executive Summary of Persistent Corneal Epithelial Defects
5. Organizations contributing towards Persistent Epithelial Defect
6. Disease Backgroung and Overview
6.1. Introduction
6.2. Etiology
6.3. Clinical Presentation
6.4. Pathophysiology
6.5. Diagnosis
6.5.1. Differential diagnosis
7. Unmet Needs
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. 7MM Total Incident Patient Population of Persistent Corneal Epithelial Defects
8.3. Assumption and Rationale
8.4. The United States
8.4.1. Incident Cases of Persistent Corneal Epithelial Defects in the United States
8.4.2. Incident cases of PED based on Gender in the United States
8.4.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in the United States
8.5. EU5
8.6. Germany
8.6.1. Incident Cases of Persistent Corneal Epithelial Defects in Germany
8.6.2. Incident cases of PED based on Gender in Germany
8.6.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Germany
8.7. France
8.7.1. Incident Cases of Persistent Corneal Epithelial Defects in France
8.7.2. Incident cases of PED based on gender in France
8.7.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in France
8.8. Italy
8.8.1. Incident Cases of Persistent Corneal Epithelial Defects in Italy
8.8.2. Incident cases of PED based on Gender in Italy
8.8.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Italy
8.9. Spain
8.9.1. Incident Cases of Persistent Corneal Epithelial Defects in Spain
8.9.2. Incident cases of PED based on Gender in Spain
8.9.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Spain
8.10. United Kingdom
8.10.1. Incident Cases of Persistent Corneal Epithelial Defects in the United Kingdom
8.10.2. Incident cases of PED based on Gender in the United Kingdom
8.10.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in the United Kingdom
8.11.Japan
8.11.1. Incident Cases of Persistent Corneal Epithelial Defects in Japan
8.11.2. Incident cases of PED based on Gender in Japan
8.11.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Japan
9. Current Treatment Practices
10. Patient Journey
11. Case Report
12. Marketed Therapies
12.1. OXERVATE: Dompe Farmaceutici
12.1.1. Product Description
12.1.2. Regulatory Milestones
12.1.3. Other Developmental Activities
12.1.4. Clinical Development
12.1.5. Safety and Efficacy
12.1.6. Product Profile
13. Emerging Products
13.1. Nexagon: OcuNexus Therapeutics/Eyevance Pharmaceuticals
13.1.1. Drug Descriptions
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Clinical Trials Information
13.1.5. Safety and Efficacy
13.1.6. Product Profile
13.2. ST266: Noveome Biotherapeutics
13.2.1. Drug Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Clinical Trials Information
13.2.5. Safety and Efficacy
13.2.6. Product Profile
13.3. RGN-259: RegeneRx Biopharmaceuticals
13.3.1. Drug Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Clinical Trials Information
13.3.5. Safety and Efficacy
13.3.6. Product Profile
13.4. REC-0559: Recordati Rare Diseases/Mimetech
13.4.1. Drug Descriptions
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Clinical Trials Information
13.4.5. Safety and Efficacy
13.4.6. Product Profile
14. Persistent Corneal Epithelial Defects: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Size of Persistent Corneal Epithelial Defects in 7MM
14.3. Market Size of Persistent Corneal Epithelial Defects by Therapies
15. Market Outlook
15.1. United States Market Size
15.1.1. Total Market Size of Persistent Corneal Epithelial Defects in United States
15.1.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in United States
15.2. EU-5 Market Size
15.3. Germany
15.3.1. Total Market size of Persistent Corneal Epithelial Defects in Germany
15.3.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Germany
15.4. France
15.4.1. Total Market size of Persistent Corneal Epithelial Defects in France
15.4.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in France
15.5. Italy
15.5.1. Total Market size of Persistent Corneal Epithelial Defects in Italy
15.5.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Italy
15.6. Spain
15.6.1. Total Market size of Persistent Corneal Epithelial Defects in Spain
15.6.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Spain
15.7. United Kingdom
15.7.1. Total Market size of Persistent Corneal Epithelial Defects in United Kindgom
15.7.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in United Kingdom
15.8. Japan
15.8.1. Total Market size of Persistent Corneal Epithelial Defects in Japan
15.8.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Japan
16. Market Drivers
17. Market Barriers
18. KOL Views
19. SWOT Analysis
20. Appendix
20.1. Bibliography
21. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/